Minimal Residual Disease Market Summary
The Minimal Residual Disease market size in the 7MM was approximately USD 700 million in 2021. The Minimal Residual Disease market is expected to expand at a healthy growth rate during the forecast period (2023-2032), owing to the launch of new therapies and technologies in the market and the rise in the number of cases.
Several major pharma and biotech companies, such as Adaptive Biotechnologies, Bristol-Myers Squibb Company, Natera, Kite Pharma, and Amgen Inc., among others, are actively working in the Minimal Residual Disease market.
Explore DelveInsight’s Full Coverage on the Minimal Residual Disease Market
Minimal Residual Disease Overview
Minimal residual disease (MRD) refers to the small number of cancer cells that remain in the body after treatment. The number of remaining cells may be so small that they do not cause any physical signs or symptoms and often cannot even be detected through traditional methods, such as viewing cells under a microscope and/or tracking abnormal serum proteins in the blood. An MRD-positive test result means that residual disease was detected, while a negative result means that residual disease was not detected.
Minimal Residual Disease Diagnosis
Minimal Residual Disease (MRD) Diagnosis refers to the detection of a very small number of cancer cells that remain in the body after treatment, even when the patient appears to be in complete remission. Advanced diagnostic techniques such as flow cytometry, polymerase chain reaction (PCR), and next-generation sequencing (NGS) enable highly sensitive identification of residual disease. MRD diagnosis plays a crucial role in assessing treatment response, predicting relapse risk, guiding personalized therapy decisions, and improving long-term outcomes in hematologic malignancies such as leukemia, lymphoma, and multiple myeloma.
Minimal Residual Disease Treatment
Minimal Residual Disease Treatment focuses on eliminating the small number of cancer cells that remain in the body after initial therapy and are often undetectable using conventional diagnostic methods. Effective treatment strategies may include targeted therapies, immunotherapies, monoclonal antibodies, CAR-T cell therapy, stem cell transplantation, or maintenance therapy, depending on the type of cancer. Advances in minimal residual disease (MRD) detection technologies enable personalized treatment decisions, helping reduce relapse risk, improve long-term survival, and optimize patient outcomes across hematologic malignancies and selected solid tumors.
Download the Sample PDF to Get More Insight on the Minimal Residual Disease Market
Minimal Residual Disease Market Players
Key companies operating in the Minimal Residual Disease market research landscape include:
- Adaptive Biotechnologies
- Bristol-Myers Squibb Company
- Natera
- Kite Pharma
- Amgen Inc.
- And Others
Minimal Residual Disease Epidemiology
The epidemiology section of the Minimal Residual Disease market report provides historical and forecasted patient population data across the seven major markets (7MM) – the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan – for the study period 2019-2032, supported by key opinion leader perspectives and disclosed assumptions.
Key Findings:
- As per the American Cancer Society (2022), there were 34,470 new cases of multiple myeloma in the United States in 2022
- About 6,660 new cases of acute lymphocytic leukemia (ALL) were reported in the US in 2022
- As per the Leukemia and Lymphoma Society, 90,390 new lymphoma cases were expected to be diagnosed in the United States in 2021, of which 8,830 cases were of Hodgkin lymphoma and 81,560 cases of non-Hodgkin lymphoma
- The epidemiology segmentation covers total MRD testing, total MRD cases by cancer type, total MRD testing across different blood cancers, total MRD testing for HSCT-related transplant, total MRD testing during new therapy and maintenance therapy, and total MRD testing by age
Minimal Residual Disease Market Outlook
According to DelveInsight, the Minimal Residual Disease market in the 7MM is expected to witness a major change during the study period 2019-2032. The market outlook builds a detailed comprehension of the historic, current, and forecasted market trends by analyzing the impact of current MRD therapies on the market, unmet needs, drivers and barriers, and demand for better technology.
This section evaluates each marketed product and late-stage pipeline therapy based on annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing market need, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, and views of key opinion leaders – regionally analyzed across the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Marketed Minimal Residual Disease Products
The Minimal Residual Disease market report provides details of the marketed products/off-label approaches available for Minimal Residual Disease testing and treatment, including:
- ClonoSEQ – Adaptive Biotechnologies
- PhasED-Seq – Foresight Diagnostics
- Targeted Locus Amplification (TLA) technology – Cergentis B.V.
- MRDx BCR-ABL Test – ICON plc
- TRUPCR® PML-RARA – 3B BlackBio Biotech India
- Signatera – Natera
- Leukemia Fusion Gene One-Step Detection Kits – EntroGen
- CBFB/MYH11 inv(16) – Quest Diagnostics
- Seq-MRD – ImmuQuad
- LymphoTrack – Invivoscribe Inc.
- Idylla Technology – Biocartis
Emerging Minimal Residual Disease Products
The Minimal Residual Disease market report provides details of the emerging technologies and products under late- and mid-stage development for Minimal Residual Disease testing and treatment.
Minimal Residual Disease Products Uptake
This section focuses on the rate of uptake of potential Minimal Residual Disease products recently launched or expected to launch during the study period 2019-2032. The analysis covers market uptake by product, patient uptake by therapies, and sales of each product, helping to understand which products are seeing the most rapid uptake, the reasons behind maximal use of new products, and comparison across products on the basis of market share and size – insights useful for financial and regulatory decision-making.
Get a Detailed Analysis of the Minimal Residual Disease Market Forecast
Conclusion
The Minimal Residual Disease market in the 7MM is poised for a healthy growth trajectory through 2032, supported by rising cancer incidence, growing awareness, and continued advancement of testing technologies. With key players such as Adaptive Biotechnologies, Bristol-Myers Squibb, Natera, Kite Pharma, and Amgen actively engaged in this space, and a broad set of products including ClonoSEQ, Signatera, PhasED-Seq, and others driving testing adoption, the market is expected to witness meaningful transformation across the United States, EU5, and Japan. As reimbursement pathways evolve and competitive intelligence continues to shape market entry strategies, the Minimal Residual Disease market presents significant opportunities for stakeholders across the diagnostic and therapeutic landscape.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Contact Person: Abhishek kumar
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com
